Preliminary Exploration on Silencing of Microrna-222 for Improving Liver Fibrosis in a Murine Model of Biliary Atresia

Shen Wenjun,Dong Rui,Chen Gong,Zhao Rui,Wang Jiang,Zheng Shan

DOI: https://doi.org/10.3760/cma.j.issn.0253-3006.2015.04.013

2015-01-01

Abstract:Objective To improve liver fibrosis by silencing of MicroRNA-222 (miR-222)through an intraperitoneal injection of antagomirl.Methods Newborn Balb/C mice were randomized into 2 groups.Both groups were infected intraperitoneally with RRV during the first 24 hours.The experimental group received an intraperitoneal injection of antagomir while the control group had normal saline instead.The growth patterns and clinical features were observed.The histologic sections were examined after 14 days.The expression of miR-222 was detected by real time polymerase chain reaction (PCR).Results Fifteen control mice (75％) showed the signs of cholestasis,retardation and extrahepatic biliary atrasia (BA).And 14 (70％) experimental mice had BA.There was no inter-group statistical difference in weight,modeling rate or natural death.The miR-222 activity was suppressed in the experimental group (1.49 ± 0.25 vs 1.86 ± 0.43,P =0.041).And it had lower liver fibrosis score (0.83 ± 0.408 vs 1.38 ± 0.518,P =0.056),especially in portal area (1.50 ± 0.548 vs 2.50 ± 0.926,P =0.037).Conclusions An intraperitoneal injection of antagomir can inhibit the miR-222 activity safely and specificity.And liver fibrosis improves to some extent in a murine BA model.